Key result
Pilot community pharmacy clopidogrel pharmacogenetic program begins enrollment to evaluate feasibility.
Why the study?
The feasibility and implementation of a pharmacogenetic program for clopidogrel in a community pharmacy setting were not previously described.
Answers are grounded in this paper and cite their sources.
Community pharmacists may be valuable partners in implementing pharmacogenetic testing for clopidogrel.
AIM: To describe the exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. An institutional review board-approved protocol for a clopidogrel pharmacogenetic program in a community pharmacy was developed to address feasibility and evaluate the pilot program. STUDY CONCEPT: Subjects taking clopidogrel are asked to participate at the point of medication dispensing. A pharmacist schedules an appointment with subjects to discuss the study and collects a buccal swab sample for CYP2C19 testing. When the results are available, the pharmacist consults with the subject's prescriber regarding test result interpretation and associated recommendations, and schedules a second appointment with the participant to discuss results and review any physician-approved therapeutic changes. The intervention-associated consultation is then billed to the subject's insurance. RESULTS: Subject enrollment has begun. CONCLUSION: Community pharmacists may be valuable partners in pharmacogenetics.
No takes yet. Share an insight, caveat, or question.
O’Connor et al. (2012) studied Subjects taking clopidogrel. Clopidogrel pharmacogenetic program (CYP2C19 testing) was evaluated. A pilot clopidogrel pharmacogenetic program in a community pharmacy has been developed and subject enrollment has begun to evaluate its feasibility.
Synapse has enriched 10 related papers. Consider them for comparative context: